Current Report Filing (8-k)
16 November 2022 - 08:49AM
Edgar (US Regulatory)
0000727207 false 0000727207 2022-11-14
2022-11-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act
of 1934
Date of report (Date of earliest event reported) November
14,
2022
Accelerate Diagnostics, Inc.
(Exact name of registrant as specified in charter)
Delaware
(State or other jurisdiction of incorporation)
|
001-31822 |
|
84-1072256 |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
3950 South Country Club Road,
Suite 470,
Tucson,
Arizona |
|
85714 |
|
(Address of principal executive offices) |
|
(Zip Code) |
(520)
365-3100
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
|
¨ |
Written communications pursuant to
Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
|
¨ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
Trading Symbol |
Name of each exchange on which
registered |
|
Common Stock, $0.001 par value per share |
AXDX |
The Nasdaq Stock Market LLC
(The Nasdaq Capital Market)
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
¨
|
Item
2.02. |
Results of Operations and
Financial Condition. |
On November 14, 2022, Accelerate Diagnostics, Inc. (the
“Company”) issued a press release announcing its financial results
for the quarter ending September 30, 2022 and hosted a
conference call to discuss such results. A copy of the press
release is attached hereto as Exhibit 99.1 and a copy of the
transcript of the conference call is attached hereto as
Exhibit 99.2, each of which is incorporated herein by
reference in its entirety.
In accordance with General Instruction B.2 for Form 8-K, the
information in this Item 2.02, including Exhibits 99.1 and 99.2,
shall not be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”),
or otherwise subject to the liabilities of that section, nor shall
it be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except as
expressly set forth by specific reference in such filing.
|
Item
9.01 |
Financial Statements and
Exhibits. |
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
| |
ACCELERATE DIAGNOSTICS, INC.
(Registrant) |
| Date: November 15, 2022 |
|
| |
/s/ Steve Reichling |
| |
Steve Reichling |
| |
Chief Financial Officer |
Accelerate Diagnostics (NASDAQ:AXDX)
Historical Stock Chart
From Feb 2023 to Mar 2023
Accelerate Diagnostics (NASDAQ:AXDX)
Historical Stock Chart
From Mar 2022 to Mar 2023
